Clinical Trials

Searchable database of currently enrolling clinical trials

Maintenance therapy and beyond with avelumab…

Evan Y. Yu
September 28, 2021

Avelumab initially received regulatory approval for patients with metastatic urothelial carcinoma in the post-platinum chemotherapy setting based on an objective response rate of 16.5%.1  In the post-platinum chemotherapy setting, both nivolumab and pembrolizumab also currently retain their regulatory approval status.  However, the situation where avelumab has the strongest data is in the maintenance-switch setting.  I initially discussed that topic in a Urotoday Clinical Trials Portal article almost 4 years ago.2  Of course, everything discussed in that article has been completed, and all highlighted trials were positive.


Dr. Evan Yu, MD

Evan Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine
  • Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
  • Clinical Research Director, Genitourinary Oncology, Seattle Cancer Care Alliance
  • Medical Director, Clinical Research Service, Fred Hutchinson Cancer Research Consortium
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.